NCT00404508View on ClinicalTrials.gov

A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2005

Study Completion Date

October 31, 2006

Conditions
Refractory Solid Tumors
Interventions
DRUG

Hydralazine and magnesium valproate

Trial Locations (1)

14080

National Institute of Cancerologia, Mexico City

All Listed Sponsors
collaborator

Psicofarma S.A. de C.V.

OTHER

collaborator

National Council of Science and Technology, Mexico

OTHER

lead

National Institute of Cancerología

OTHER_GOV

NCT00404508 - A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors | Biotech Hunter | Biotech Hunter